Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs 3M Company — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while 3M Company trades at $156.2 (market cap $81.67B). The key difference: 3M Company is far larger — about 10.2× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and 3M Company pays a 1.99% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | MMM | |
|---|---|---|
Market Cap | $8.04B | $81.67B |
Sector | Health | Industrials |
52-Week High | $339.75 | $174.61 |
52-Week Low | $241.71 | $141.10 |
Enterprise Value | $7.85B | $90.07B |
Dividend Yield | — | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
3M (MMM) trades at $157.70, showing minimal daily movement with a 0.11% gain. The stock faces technical headwinds with bearish moving averages but maintains strong profitability metrics including a 72.14% ROE and consistent earnings beats. Recent developments include new product launches and strategic partnerships, though the company navigates consumer segment weakness and mixed analyst sentiment.
The outlook remains balanced with solid fundamentals supporting long-term value, but near-term risks include competitive pressures and macroeconomic sensitivity. Analyst consensus suggests cautious optimism with a $143 price target, while technical indicators signal potential consolidation around current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
